The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.
Novartis has officially broken ground on a 700,000-square-foot-plus flagship manufacturing hub that is expected to provide end-to-end manufacturing services.1 The project—originally unveiled last month2—will feature the design of a new Morrisville plant, along with a new site in Durham that will include two facilities of its own.
Strengthening the US pharma supply chain
The services of the current Durham plant will also be grown—featuring gene therapy production as it stands—by expanding its services to include the sterile filling of biologics into syringes and vials. These new investments are expected to create 700 new Novartis jobs in the state, along with more than 3,000 indirect jobs across the supply chain by the end of the decade.
The strategic investment is part of the company’s greater mission to investment $23 billion over the next five years toward US infrastructure, while also serving as a way to strengthen the US pharma supply chain…